Novozymes Biopharma will present the company's latest research into the development of proteins with extended circulatory half-life at the Next Generation Protein Therapeutics Summit 2011.
The presentation, which offers new insight into the production of albumin fusions, will describe Novozymes' new Albufuseflex technology.
The technology is expected to have applications in drug delivery, where it may be used to tailor drug half life, thereby enhancing effectiveness while improving patient quality of life.
The presentation, entitled 'Albumin fusions: a simple, broad platform for the production of proteins with extended circulatory half-life', will be presented by Les Evans, scientific manager, Novozymes Biopharma on 22 June at 1pm.
Short circulatory half-life is a major challenge for the therapeutic use of many peptides and proteins.
Recombinant fusions of such molecules to albumin have demonstrated significantly enhanced pharmacokinetic profiles alongside bioactivity.
The presentation will describe advances in the production of albumin fusions that will further enhance their potential in protein and peptide delivery.
